Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CRVO Stock Forecast 2026-2027
$3.89
Current Price
$36.02M
Market Cap
Buy 8
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CRVO Price Targets
+696.9%
To High Target of $31.00
+439.8%
To Median Target of $21.00
+182.8%
To Low Target of $11.00
CRVO Price Momentum
-3.7%
1 Week Change
-3.2%
1 Month Change
-55.8%
1 Year Change
-50.8%
Year-to-Date Change
-70.4%
From 52W High of $13.13
+10.8%
From 52W Low of $3.51
📊 TOP ANALYST CALLS
Did CRVO Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Cervomed is one of their latest high-conviction picks.
Latest CRVO Stock Price Targets & Analyst Predictions
Based on our analysis of 11 Wall Street analysts, CRVO has a bullish consensus with a median price target of $21.00 (ranging from $11.00 to $31.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $3.89, the median forecast implies a 439.8% upside. This outlook is supported by 8 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jason Kolbert at D. Boral Capital, projecting a 696.9% upside. Conversely, the most conservative target is provided by Boobalan Pachaiyappan at Roth Capital, suggesting a 182.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CRVO Analyst Ratings
8
Buy
0
Hold
0
Sell
CRVO Price Target Range
Low
$11.00
Average
$21.00
High
$31.00
Current: $3.89
Latest CRVO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CRVO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 8, 2026 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $31.00 |
| Mar 19, 2026 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $31.00 |
| Mar 18, 2026 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $21.00 |
| Mar 18, 2026 | Roth Capital | Boobalan Pachaiyappan | Buy | Maintains | $11.00 |
| Mar 16, 2026 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $31.00 |
| Mar 5, 2026 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $15.00 |
| Mar 4, 2026 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $31.00 |
| Feb 18, 2026 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $31.00 |
| Dec 18, 2025 | Cantor Fitzgerald | Pete Stavropoulos | Overweight | Initiates | $N/A |
| Dec 18, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $25.00 |
| Dec 5, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $31.00 |
| Dec 2, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $31.00 |
| Nov 11, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $31.00 |
| Nov 5, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Upgrade | $25.00 |
| Nov 4, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $31.00 |
| Sep 8, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Neutral | Reiterates | $11.00 |
| Aug 18, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $31.00 |
| Aug 12, 2025 | Roth Capital | Boobalan Pachaiyappan | Buy | Reiterates | $16.00 |
| Aug 11, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $15.00 |
| Aug 11, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $15.00 |
CervoMed Inc. (CRVO) Competitors
The following stocks are similar to Cervomed based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CervoMed Inc. (CRVO) Financial Data
CervoMed Inc. has a market capitalization of $36.02M with a P/E ratio of 4.9x. The company generates $4.01M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -99.6% quarter-over-quarter, while maintaining an operating margin of -95,479.2% and return on equity of -93.9%.
Valuation Metrics
Market Cap
$36.02M
Enterprise Value
$15.99M
P/E Ratio
4.9x
PEG Ratio
-2.4x
Price/Sales
9.4x
Growth & Margins
Revenue Growth (YoY)
-99.6%
Gross Margin
N/A
Operating Margin
-95,479.2%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+57.9%
Current Ratio
4.9x
Debt/Equity
0.0x
ROE
-93.9%
ROA
-53.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
CervoMed Inc. (CRVO) Business Model
About CervoMed Inc.
What They Do
Develops treatments for neurodegenerative diseases.
Business Model
The company operates in the biotechnology sector, focusing on the research and development of innovative therapies for neurodegenerative diseases like Alzheimer's and Parkinson's. It generates revenue through partnerships and collaborations with academic institutions, healthcare providers, and industry partners aimed at advancing medical research and therapeutic solutions.
Additional Information
CervoMed Inc. is recognized for its scientific expertise in neurotherapeutics and aims to improve patient outcomes by exploring new pathways for treatment. The company's work contributes significantly to the understanding of neurobiology and the development of targeted interventions for debilitating neurological disorders.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
15
CEO
Dr. John J. Alam M.D.
Country
United States
IPO Year
2023
Website
www.cervomed.comCervoMed Inc. (CRVO) Latest News & Analysis
Latest News
Quick Summary
The update will provide new MRI analyses from the Phase 2b RewinD-LB trial, details on global regulatory discussions, and the finalized design for the Phase 3 trial.
Why It Matters
New MRI analyses and progress on regulatory discussions signal potential advancements in clinical trials, impacting the company's valuation and future growth prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
1 month ago
Quick Summary
CervoMed Inc. reported positive Phase 2b data for its neflamapimod program in DLB and aligned with regulators for a Phase 3 trial. Multiple catalysts expected in H2 2026.
Why It Matters
Positive clinical results and FDA alignment signal potential advancements in drug development, which could boost market confidence and stock value for CervoMed as trial milestones approach.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Phase 2b trial results indicate DLB patients with lower plasma pTau181 levels showed greater clinical benefit from neflamapimod, suggesting an earlier disease stage without Alzheimer's co-pathology.
Why It Matters
Lower pTau181 levels in DLB patients suggest a more favorable response to neflamapimod, potentially indicating a breakthrough treatment, impacting biotech stock valuations and future investment strategies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
CervoMed Inc. (CRVO) reported a quarterly loss of $0.88 per share, exceeding the Zacks Consensus Estimate of a $0.79 loss, and compared to a loss of $0.80 per share last year.
Why It Matters
CervoMed's larger-than-expected quarterly loss signals potential operational challenges and may impact investor confidence, affecting the stock's performance.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
CervoMed Inc. completed a Phase 1 study of a new stable crystal form of neflamapimod, confirming its pharmacokinetic profile for a Phase 3 trial in dementia with Lewy bodies at 50mg TID.
Why It Matters
Successful Phase 1 results and planned Phase 3 dosing for neflamapimod may enhance CervoMed's prospects in treating dementia, potentially increasing stock value and investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors
2 months ago
Quick Summary
CERo Therapeutics Holdings, Inc. (OTCQB: CERO) appointed Eric Francois to its Board of Directors, as announced on February 17, 2026.
Why It Matters
The appointment of Eric Francois to CERo's Board may indicate a strategic move to enhance governance and expertise, potentially influencing company direction and investment attractiveness.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About CRVO Stock
What is CervoMed Inc.'s (CRVO) stock forecast for 2026?
Based on our analysis of 11 Wall Street analysts, CervoMed Inc. (CRVO) has a median price target of $21.00. The highest price target is $31.00 and the lowest is $11.00.
Is CRVO stock a good investment in 2026?
According to current analyst ratings, CRVO has 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.89. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CRVO stock?
Wall Street analysts predict CRVO stock could reach $21.00 in the next 12 months. This represents a 439.8% increase from the current price of $3.89. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is CervoMed Inc.'s business model?
The company operates in the biotechnology sector, focusing on the research and development of innovative therapies for neurodegenerative diseases like Alzheimer's and Parkinson's. It generates revenue through partnerships and collaborations with academic institutions, healthcare providers, and industry partners aimed at advancing medical research and therapeutic solutions.
What is the highest forecasted price for CRVO CervoMed Inc.?
The highest price target for CRVO is $31.00 from Jason Kolbert at D. Boral Capital, which represents a 696.9% increase from the current price of $3.89.
What is the lowest forecasted price for CRVO CervoMed Inc.?
The lowest price target for CRVO is $11.00 from Boobalan Pachaiyappan at Roth Capital, which represents a 182.8% increase from the current price of $3.89.
What is the overall CRVO consensus from analysts for CervoMed Inc.?
The overall analyst consensus for CRVO is bullish. Out of 11 Wall Street analysts, 8 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $21.00.
How accurate are CRVO stock price projections?
Stock price projections, including those for CervoMed Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 22, 2026 7:02 AM UTC